Viridian Therapeutics Inc Stock

$23.33

1.17% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US92790C1045

Symbol

VRDN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Viridian Therapeutics Inc Stock price

$23.33

+11.75 101.44% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+0.27 1.17%

ISIN

US92790C1045

Symbol

VRDN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.76b
Enterprise Value	$1.37b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	4,721.59
P/S ratio (TTM) P/S ratio	6,071.66
P/B ratio (TTM) P/B ratio	3.84
Revenue growth (TTM) Revenue growth	-82.59%
Revenue (TTM) Revenue	$290.00k
EBIT (operating result TTM) EBIT	$-237.88m
Free Cash Flow (TTM) Free Cash Flow	$-168.20m
Cash position	$571.37m
EPS (TTM) EPS	$-4.51
P/E forward	negative
P/S forward	6,233.69
EV/Sales forward	4,847.59
Short interest	14.76%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Viridian Therapeutics Inc forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Viridian Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '24		+/- %
Revenue	0.29 0.29	82% 82% 100%
- Direct Costs	1.46 1.46	- 503%
Gross Profit	-1.17 -1.17	- -403%
- Selling and Administrative Expenses	86 86	78% 78% 29,597%
- Research and Development Expense	149 149	12% 12% 51,521%
EBITDA	-236 -236	- -81,521%
- Depreciation and Amortization	1.46 1.46	- 503%
EBIT (Operating Income) EBIT	-238 -238	32% 32% -82,026%
Net Profit	-218 -218	27% 27% -75,217%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Viridian Therapeutics Inc Stock News

Positive

Seeking Alpha

●

8 days ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the para...

Neutral

Business Wire

●

16 days ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferr...

Positive

Seeking Alpha

●

17 days ago

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 bil...

More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office	United States
CEO	Stephen Mahoney
Employees	96
Founded	2006
Website	www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now